Delving into the Latest Updates on Human Coagulation Factor IX(Guangdong Shuanglin Biological) with Synapse

Overview

Basic Info

Drug Type

Non-recombinant coagulation factor

Synonyms-

Target

factor IX

Mechanism

factor IX modulators(Coagulation factor IX modulators)

Therapeutic Areas

Congenital DisordersHemic and Lymphatic DiseasesOther Diseases

Active Indication

Hemophilia B

Inactive Indication-

Originator Organization

Guangdong Shuanglin Biological Pharmaceutical Co. Ltd.

Active Organization

Guangdong Shuanglin Biological Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

The primary objective is to evaluate the efficacy and safety of on-demand replacement therapy of human coagulation factor IX in patients with moderate to severe hemophilia B. The secondary objective is to observe the pharmacokinetic characteristics of human coagulation factor IX after a single dose in patients with moderate to severe hemophilia B and calculate the pharmacokinetic parameters.

Start Date19 Jan 2024

Sponsor / Collaborator

Guangdong Shuanglin Biological Pharmaceutical Co. Ltd.

100 Clinical Results associated with Human Coagulation Factor IX(Guangdong Shuanglin Biological)

Login to view more data

100 Translational Medicine associated with Human Coagulation Factor IX(Guangdong Shuanglin Biological)

Login to view more data

100 Patents (Medical) associated with Human Coagulation Factor IX(Guangdong Shuanglin Biological)

Login to view more data

100 Deals associated with Human Coagulation Factor IX(Guangdong Shuanglin Biological)

Login to view more data